Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer
NCT07287592Phase 3Not yet recruiting
- Sponsor
- Ain Shams University
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of glutamine in vincristine-induced neuropathy (VIPN) (2 arms), sponsored by Ain Shams University. Primary endpoints: Safety outcome at 12 months and Primary objective outcome at 3 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
glutamine
03
Conditions
vincristine-induced neuropathy (VIPN)
Beyond the preview
Go deeper on NCT07287592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07287592.